Endometrial cancer is the most common gynecological cancer and the fourth most common cancer in women worldwide. In spite of its' relative importance to overall morbidity among women, molecular research in endometrial cancers lags far behind other cancers such as breast and colorectal. Nowhere is this more true than in research in the newly emergent field of posttranscriptional gene regulation by small, regulatory RNAs, primarily microRNAs (miRNAs). Here, structure, biogenesis, and mode of action of miRNAs are presented along with a brief overview of the role of miRNAs in carcinogenesis and a review of the few miRNA studies in endometrial cancer carried out to date.
Introduction
In a now classic review paper, Hanahan and Weinberg 1 outlined what they considered to be the hallmarks of cancer. These hallmarks, that are acquired by cancer cells, are 1. self-sufficiency in growth signals, the ability of cancer cells to promote their own growth, 2. insensitivity to anti-growth signals, the ability of cancer cells to ignore homeostatic signals, 3. evasion of apoptosis, the ability of cancer cells to ignore programmed cell death, 4. limitless replicative potential, the ability of cancer cells to grow unchecked, 5 . sustained angiogenesis, the ability of cancer cells to supply themselves with resources such as oxygen and nutrients, and 6. tissue invasion and metastasis, the ability of cancer cells to colonize other regions of the body. Not all cancer cells will acquire these characteristics at the same rate nor will they acquire them in the same order nor will they acquire them by the same mechanisms thus making cancers a very heterogenous group of diseases with individual and quite variable characteristics. However, from the list of acquired characteristics presented above it is abundantly clear that the one thing that cancer cells do have in common from the very beginning is that they do not behave the same way that non-cancer cells do.
Normal cells, whether they be skin cells, neurons, kidney, or uterus, maintain their individual integrity, respond to their micro-and macroenvironments, and interact with other cells according to a set of internally and externally driven programs designed to sustain equilibria that were established over more than three billion years of evolution.
Cancer cells seem not to obey many of these rules, they create their own set of programs that ignore the established principles of cellular response and interaction. They are, in essence, an invasive species for which the equilibria of the environment in which they find themselves are irrelevant. Yet, cancer cells are not aliens that dropped in from an alternate universe. Indeed, cancer cells are ultimately all descended from perfectly normal cells that obeyed all of the rules. Thus, the rules that cancer cells follow are not written de novo but are, rather, re-written from the normal rules.
The rules of cellular behavior are enforced by a single primary agency. Most of the actions and reactions carried out in any cell are implemented by proteins. Cellular proteins are present in the cells in a bewildering array of sizes, functions, and amounts yet all of these proteins ultimately arise from the primary messages carried in the genes. The DNA sequences that encode the proteins are first transcribed into an RNA message which is, in turn, translated into the specific amino acid sequence of a protein and this is done in a carefully managed amount necessary for the cell to function. The checks and balances on the amounts of the various proteins required for a specific cell to function reside at three levels. At the DNA level there are elegant feed back systems that determine the time, the place, and the amount of transcription of genomic DNA into RNA. At the protein level there is an equally elegant system in which the primary amino acid sequences of proteins are processed into mature proteins able to carry out their specific functions. This is accompanied by cell-and tissuespecific mechanisms for protein transport as well as protein-protein and protein-RNA interactions. Until recently, it was believed that these two levels of control were all that the cell had at its disposal. In the past few years we have become aware of a level of control that lies in between the two we knew. This began in 1993 in the laboratory of Victor Ambros with the chance discovery in the tiny worm Caenorhabtidis elegans of a very short RNA sequence that, instead of coding for a protein, was capable of regulating the translation of the messenger RNA of another gene into its protein. This was a completely unknown level of control, now called post-transcriptional gene regulation, which has been found to be a ubiquitous and powerful mechanism throughout both the animal and plant kingdoms. In human and other animal cells, the primary agent of this posttranscriptional gene regulation is the microRNA (miRNA). Here, we present the structure, biosynthesis, and mechanism of action of miRNAs, discuss the current level of understanding of the role of miRNAdirected gene regulation in cancer, and, finally, the status of miRNA research in endometrial cancers. miRNA structure, biosynthesis, and mode of action [7] [8] [9] .
MicroRNA biogenesis (figure 1) begins with the RNA polymerase II directed production of a primary RNA transcript (pri-miRNA) that can be several thousands of nucleotides in length and be either intragenic, lying in the DNA between genes, or intronic, lying in the non-coding DNA within genes. Primary miRNA transcripts are capped and polyadenylated in the same way as protein coding mRNA transcripts 10 . The pri-miRNA transcript contains within it one (usually) or more (rarely) sequences that form characteristic thermodynamically stable hairpin structures. This hairpin structure, called the precursor or premiRNA, typically ranges in size from 60nt to 110nt (figure 1). These hairpin structures induce the formation of an RNA-protein complex, composed of the RNA hairpin, the RNase III endonuclease DROSHA, and a double-stranded RNA binding protein partner which in mammals is called DGCR8 11 . The latter protein binds the pre-miRNA and DROSHA excises it from the primary transcript. The remaining RNA in the pri-miRNA transcript is simply recycled in the nucleus. Once excised, the pre-miRNA is handed off to another nuclear protein, a Ran transport receptor protein family member called Exportin 5, which binds the hairpin and transports it from the nucleus to the cytoplasm 12 . Figure 1 . The pathway of microRNA biogenesis. A primary RNA transcript is generated by RNA polII which then capped and polyadenylated (pri-miRNA). Within this transcript a thermodynamically stable hairpin structure is formed (pre-miRNA). The hairpin structure is excised from the primary transcript through the combined action of the enzyme DROSHA and its partner DGCR8. This hairpin is passed off to a transport protein, Exportin 5, which ferries the hairpin from the nucleus to the cytoplasm. Once in the cytoplasm, the hairpin is bound by the enzyme Dicer and its partner TRBP which excises the small double-stranded RNA containing the mature miRNA and the star sequence. This is then handed off to an Argonaute protein, Ago2, which selects the mature miRNA strand and packages it into the RNA-induced silencing complex, RISC, for transport to its eventual mRNA target.
In the cytoplasm the pre-miRNA hairpin is recognized as a doublestranded RNA which induces a second RNase III endonuclease, called Dicer, which binds to the hairpin in association with another protein called TRBP (TAR RNA binding protein) and cleaves it in a precise manner to produce a small (21nt -23nt) double-stranded molecule which is composed of the mature miRNA effector and its complement called the star, or miRNA*, sequence 13, 14 . Conventional nomenclature refers to a microRNA as miR. This is preceded by the species from which it comes, for example Hsa for Homo sapiens, Mmu for the mouse species Mus musculus, and Cfa for the dog Canis familiaris. It is then followed by a number that is assigned by the curatorial miRNA database, miRBase, at the University of Manchester in the United Kingdom 4 . Many miRNAs are found in multiple species and some are quite ancient so such a nomenclature avoids a great deal of confusion. In practice, however, most miRNA are simply referred to as miR-xxx and they will be in this paper with the understanding that, for example, the designation miR-21 or miR-200c actually refers to hsa-miR-21 or hsamiR-200c.
The double-stranded RNA generated by Dicer/TRBP is nearly always imperfectly complementary, with one or more mismatched bases being the rule, and displays a 2nt 3' overhang on both strands (figure 1). This double-stranded molecule is then handed off to an Argonaute protein, called AGO2 in mammals, which is the primary component of a ribonucleoprotein complex called RISC (RNA induced silencing complex). In RISC the AGO2 protein selects the mature miRNA strand and cleaves the star strand. At this point, RISC transports the mature miRNA sequence to its target mRNA. Mature miRNAs bind in an antisense orientation to one or more locations in the 3' UTR of the mRNA where the result is either to suppress (usually) or eliminate (rarely) mRNA translation into an amino acid sequence. Complementarity of the mature miRNA sequence to its mRNA target sequence is nearly always imperfect. Indeed, it is believed that the mismatches in the miRNA/mRNA complementary sequences are necessary. There is one piece of the miRNA sequence that is quite specific, however. The 8nt RNA sequence from position two through position nine from the 5' end is called the seed and it is the seed that principally determines recognition of the miRNA and its mRNA target 5, 8 . It is through this mechanism that cells can regulate protein production even if the original DNA encoding that protein is fully transcribed into RNA.
miRNAs and Cancer: Oncogenes and Suppressors
The rapidly expanding role of miRNAs in cancer has been documented in a number of excellent recent reviews [15] [16] [17] . What is clear from these and other reviews is that miRNAs can function as both tumor suppressors and as oncogenes depending upon their targets. There are currently more than 700 human microRNAs archived in miRBase. Of these, only a handful have yet to be fully evaluated for their potential involvement in cancer. However, Calin et al. 18 showed that more than half of the then known human miRNAs were located in cancerassociated genome regions or in fragile sites. Over the past few years, a number of specific human miRNAs have been shown to be differentially expressed in specific cancers. For example, Ciafre et al. 19 showed that several miRNAs (notably miR-21 As noted, whether or not a specific miRNA acts as a suppressor or as an oncogene relates to the target, or targets, of that miRNA.
As a consequence of target specificity and the regulatory mechanisms involved, a miRNA can be an oncogene in one tumor and a tumor suppressor in another 28 . Two genes, HER2 and HER3, significantly associated with breast cancer survival, are suppressed by one of the human miR-125 family 29 but both miR-125a and miR-125b target other genes where their effects are likely to be oncogenic.
The previously mentioned miR-17-92 polycistronic miRNA cluster on human chromosome 13q31.3 has been implicated as oncogenic in a number of cancers 30 but miR-17 has an antitumorigenic effect in breast cancer. Other such Jekyll and Hyde miRNAs include members of the let-7 family and the miR-29 family. Clearly, the role of miRNAs in cancer is and will continue to be diverse and as unpredictable as the genes they target. 
MicroRNAs in Endometrial Cancer
It is not by accident or omission that the discussion of the state of knowledge of the role of miRNAs in cancer presented above did not include a single mention of endometrial cancer. Endometrial cancer is the fourth most common cancer among women worldwide 31, 32 and endometrioid adenocarcinoma accounts for 75%-80% of all endometrial cancers 33 yet examination of miRNAs in these cancers is minimal in comparison to other cancers.
In the first reported survey, Boren et al. 34 examined expression of 335 human miRNAs using a hybridization array strategy followed by qPCR validation of selected candidates on the basis of expression levels. Their study sample consisted of 61fresh frozen endometrial tissues which included 37 endometrial cancers, 20 normal endometrium, and four atypical hyperplasias. They were able to identify a total of thirteen miRNAs as either significantly overexpressed or significantly underexpressed in endometrial cancers as compared to normal endometrium. Their eight over-expressed miRNAs were let-7c, miR-103, miR-106a, miR-107, miR-181a, miR-185, miR-210 and miR-423 and their five under-expressed miRNAs were let7i, miR-30c, miR-152, miR-193, and miR-221. In addition to the miRNAs, Boren et al. assessed expression levels of 22,000 messenger RNAs again using a hybridization array strategy. Ninety mRNAs were seen to be differentially expressed in endometrial cancers compared with normal endometrium and, with both sets of expression levels in hand, they were able to link twenty-six differentially expressed mRNAs to their differentially expressed miRNAs by confirming that the mRNAs were predicted targets of one or more of the miRNAs. These miRNA::mRNA pairings have, as yet, to be experimentally confirmed.
Wu et al. 35 employed a similar hybridization array strategy to assess differential expression among 469 miRNAs in endometrial cancers. Their survey revealed 17 overexpressed miRNAs and six underexpressed miRNAs in a sample composed of ten endometrioid adenocarcinomas each paired with normal endometrium from the same patients. In addition, they selected six of the 23 miRNAs for subsequent qPCR validation. From the validations they observed that miR-205 was eighteen-fold overexpressed in the cancers and that miR-449 and miR-429 were sixteenfold and fifteen-fold over-expressed respectively.
In the opposite direction, miR-99b and miR-204 were seen to be less than 0.3-fold expressed in the cancers compared to the normal endometrium.
Using a different approach, that of direct qPCR assessments of miRNA expression levels, Chung et al. 36 surveyed 157 miRNAs in fresh frozen tissues composed of 22 normal endometrium and 30 endometrioid adenocarcinomas. They reported that thirty of the 157 miRNAs were significantly overexpressed in the cancers and they carried out subsequent validations of fourteen (miR-95, miR-103, miR106a, miR-151, miR-155, miR-182, miR-183, miR-194, miR-200a, miR200c, miR-203, miR-205, and miR-210) . As in the Wu et al. study, the most highly over-expressed microRNA was miR-205 which, in these samples was more than 25-fold over-expressed in the adenocarcinomas than in the normal endometrium. Others included miR-182 (>8-fold), miR-325 (8-fold), and miR-183 (7-fold).
The most ambitious miRNA survey in endometrial cancer to date was recently reported by Hiroki et al. 37 . Using Agilent microRNA hybridization arrays they profiled the expression levels of 470 miRNAs in a sample of seven normal endometrium and 21 endometrial serous adenocarcinomas. This survey identified a total of 66 microRNAs that were overexpressed in the cancers compared to the normal tissues and 54 that were under-expressed in the cancers compared to the normal tissues. Among these, they chose to qPCR validate eight candidate miRNAs that were among those seen to be underexpressed (miR-10b, miR-29b, miR34b, miR-101, miR-133a, miR-133b , miR-152, and miR-411) and one, miR-205, that was very highly overexpressed (>267-fold) in the cancers compared to the normal endometrium.
Taking all four extant studies together and making allowances for differences in the methods used as well as the fact that there is no information on how much the miRNA sets overlapped, comparative miRNA expression patterns are presented in Figure 2 . As noted above, miRNA studies in endometrial cancer are few in number yet these few studies have already identified a number of candidate miRNAs for more detailed analysis. One of these, miR-200c, has proven to be very informative with regard to one of the cancer hallmarks outlined in the beginning of this review-the ability of cancer cells to colonize other regions of the body. It is this interplay between carefully designed miRNA surveys and controlled studies of candidates identified in those surveys that will lead to a much greater understanding of the role played by small regulatory RNAs in endometrial cancers.
Envoi
At the beginning of this paper it was noted that cancer cells behave differently than do normal cells and that these differences in behavior result from cancer cells essentially re-writing the rules that apply to normal cells existing in equilibrium. 44 . Such global effects can be accomplished in a number of ways including the activation of cancer-associated transcription factors like p53 and Myc which are known to have direct effects on miRNAs of the miR-34 family (p53) and miR-17 cluster (Myc). Chang et al. 45 have further shown that activation of Myc in cancer could directly reprogram the wider miRNA transcriptome. Other potential means of accomplishing miRNA reprogramming result from the massive genetic alterations known to occur in cancer cells 18, 46 and from specific alterations of the miRNA processing machinery itself 47, 48 . Thus, continued detailed studies of miRNAs in cancers will shed new light on the nature of cellular reprogramming and lead to new and more efficient ways to attack cancers in general 44 and, from our perspective, endometrial cancers in particular, in the clinic.
